BCL2 and acute myeloid leukemia: Of notable success is the Bcl-2-specific inhibitor Venetoclax (ABT-199), which has been FDA-approved for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML) [349,350,351,352,353].